EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 1
EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS
Riess case 1:
A 44-year-old female with relapsed stage IV adenocarcinoma.
- This is a 44-year-old female diagnosed with stage IV adenocarcinoma
- Tissue-based mutation testing showed an EGFR mutation with exon 19 deletion
- She was subsequently treated with afatinib
- After 11 months she became mildly symptomatic with small, nonspecific pulmonary nodules
- Follow up CT scan showed growth of the primary lesion
- The patient reported worsening of her cough
- Cell-free DNA testing was ordered and was negative for both the EGFR driver mutation and for T790M
- Subsequent tissue biopsy showed the presence of T790M
- The patient was switched to osimertinib and continues to respond well to therapy with minimal toxicity
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
